In parallel regulatory moves, the FDA expanded Pluvicto’s use into earlier mHSPC and granted Priority Review to J&J’s subcutaneous amivantamab regimen for post-platinum head and neck cancer. Together, the actions underscore continued FDA emphasis on post-therapy sequencing and route-of-administration changes that can increase access. At the policy level, U.S. lawmakers moved to delay Office of Management and Budget research grant rule changes through a Senate funding resolution, aiming to prevent planned modifications from taking effect until at least December 11. The legislative step reflects ongoing concerns that changes could shift funding decision power away from peer review panels. For biotech operators, the combination of label expansions and grant-policy scrutiny highlights the tight coupling between near-term commercialization opportunities and longer-term uncertainty in the research funding environment supporting pipeline generation.